ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.

Tune in to ASCO's new ASCO in Action podcast series, providing analysis and commentary on cancer policy and practice issues, available through iTunes or Google Play.

February 20, 2018

Eligible clinicians who submitted 2017 Quality performance data for the Merit-Based Incentive Payment System (MIPS) via claims can view performance scores through the MIPS data submission feature on the Quality Payment Program (QPP) website. Note: claims data submission is only an option if you’re participating in MIPS as an individual, not as part of a group.

February 20, 2018

The American Medical Association (AMA) recently launched the “Share Your Story” campaign as part of its work to end the opioid epidemic in the United States. ASCO is now accepting campaign submissions from the oncology community highlighting physician efforts to provide appropriate care in the midst of the epidemic and to urge payers and policymakers to improve access to treatment.

February 20, 2018

On February 16, 2018, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca Inc.) for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. 

February 16, 2018

On Feb. 16, 2018, JCO Clinical Cancer Informatics (JCO CCI) published its first special collection of articles. This collection highlights ways in which sharing cancer research data is now possible through individual networks, including ASCO’s CancerLinQ®.

February 15, 2018

On February 12, the White House released its Fiscal Year (FY) 2019 budget proposal, which included several provisions and budget changes of interest to the cancer community. While the proposal is not binding, it does provide a view into some of the Administration’s goals and budget priorities for the year. 

February 14, 2018

Biosimilars have rapidly proliferated in the cancer care landscape, leaving many providers unclear about the full impact these products will have on the care they deliver to patients. “American Society of Clinical Oncology Statement: Biosimilars in Oncology,” published in the Journal of Clinical Oncology, examines a range of issues to help ASCO members better understand the impact of biosimilars on oncology care.

February 14, 2018

On February 14, 2018, the Food and Drug Administration approved apalutamide (Erleada™, Janssen Biotech, Inc.) for patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). 

February 14, 2018

As deadlines draw near for submitting data for the 2017 Merit-based Incentives Payment System (MIPS) performance period, CMS has created a Top Ten List of things to know and do before the March deadline, along with important dates to remember.

February 12, 2018

Robin Zon, MD, FACP, FASCO, a medical oncologist at Michiana Hematology Oncology and last year’s ASCO Advocate of the Year, joined ASCO CEO Dr. Clifford Hudis this month to discuss Congressional advocacy and the role it plays in shaping cancer-related policies.

February 12, 2018

ASCO’s Quality Oncology Practice Initiative (QOPI®) Round 1 of reporting opened for registration on Feb. 5; data abstraction will open on Tuesday, Feb. 27 and close on Friday, June 1.

February 12, 2018

Congress passed the “Bipartisan Budget Act of 2018,” which funds the federal government through March 23, 2018, raises the federal budget caps for the next two years, and addresses several policies of importance to the cancer community.

February 9, 2018

The American Society of Clinical Oncology (ASCO) commends Congress for passing a continuing resolution that includes an important correction to the Merit-based Incentive Payment System. We are also pleased to see a budget deal that commits to at least a $2 billion funding increase for the National Institutes of Health (NIH) to reclaim America’s leadership in cancer research and continue building on our tremendous progress towards understanding, preventing, and treating cancer.

February 8, 2018

On February 7, 2018, the Food and Drug Administration (FDA) approved abiraterone acetate (Zytiga®, Janssen Biotech Inc.) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). 

February 7, 2018

ASCO applauds a provision in the continuing resolution (CR) passed by the House of Representatives yesterday that will ensure that payment adjustments under the Merit-based Incentive Payment System (MIPS) are not applied to Medicare Part B drug reimbursement. ASCO has strongly advocated for this change since the release of a proposed Quality Payment Program rule by the Centers for Medicare and Medicaid Services in June of 2017

February 7, 2018

ASCO today released its review of leading oncology pathway vendors in the United States. "Oncology Clinical Pathways: Charting the Landscape of Pathway Providers," published in the Journal of Oncology Practice (JOP), examines the clinical pathways offered by six commercial vendors using the society's criteria for high-quality clinical pathways.

Pages